NCT03515512View on ClinicalTrials.gov

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 17, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

February 13, 2023

Conditions
Acute Myeloid LeukemiaChronic Myelomonocytic Leukemia
Interventions
DRUG

Enasidenib

Enasidenib may help block the over production of IDH2, which when mutated, can overproduce metabolites and compounds that contribute to the growth of tumors and cancerous cells

Trial Locations (4)

21287

Johns Hopkins Cancer Center, Baltimore

43210

Ohio State University Comprehensive Cancer Center, Columbus

02214

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT03515512 - IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter